Heiko Schipper - Bayer AG Executive
| BAYRYDelisted Stock | USD 16.86 0.86 5.37% |
Executive
Mr. Heiko Schipper was Member of the Management Board and Head of the Consumer Health Division at Bayer Aktiengesellschaft since March 1, 2018. He completed his Master in Business Economics at the Erasmus University in Rotterdam, the Netherlands. Starting in 1994, he acquired his first professional experience at Heineken. He joined Nestle as an international marketing trainee in 1996, developing his career in sales and marketing management roles in Bangladesh and Indonesia and at the company global headquarters in Switzerland. He then took up general management roles of increasing importance in the Philippines and, from 2007 to 2013, in the Greater China Region with the aim of developing Nestle position in this key market. In 2013, Mr. Schipper moved back to Switzerland to lead the global Infant Nutrition Division, a business with both consumer and medical characteristics. He was appointed to the Nestle Group Executive Board in October 2014. since 2018.
| Age | 54 |
| Tenure | 6 years |
| Phone | 49 214 30 1 |
| Web | https://www.bayer.com |
Bayer AG Management Efficiency
The company has return on total asset (ROA) of 0.0576 % which means that it generated a profit of $0.0576 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.13 %, meaning that it generated $0.13 on every $100 dollars invested by stockholders. Bayer AG's management efficiency ratios could be used to measure how well Bayer AG manages its routine affairs as well as how well it operates its assets and liabilities.Bayer AG PK has accumulated 35.55 B in total debt with debt to equity ratio (D/E) of 1.08, which is about average as compared to similar companies. Bayer AG PK has a current ratio of 1.14, suggesting that it is in a questionable position to pay out its financial obligations in time and when they become due. Debt can assist Bayer AG until it has trouble settling it off, either with new capital or with free cash flow. So, Bayer AG's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Bayer AG PK sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Bayer to invest in growth at high rates of return. When we think about Bayer AG's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Eric MD | Merck Company | 64 | |
| Andrew Barnett | AstraZeneca PLC ADR | N/A | |
| Flavius MD | Gilead Sciences | N/A | |
| Ahn Poole | Bristol Myers Squibb | 49 | |
| Alan Hippe | Roche Holding Ltd | 56 | |
| Joseph Eiden | Bristol Myers Squibb | 75 | |
| Johannes Oosthuizen | Merck Company | 56 | |
| FranoisXavier Roger | Sanofi ADR | 62 | |
| Klaus Moosmayer | Novartis AG ADR | 56 | |
| Giovanni MD | Bristol Myers Squibb | 59 | |
| William Winters | Novartis AG ADR | 60 | |
| Thomas Larsen | Sanofi ADR | 50 | |
| Dalton III | Merck Company | 57 | |
| Karenann Terrell | GlaxoSmithKline PLC ADR | 58 | |
| Charles Sawyers | Novartis AG ADR | 62 | |
| Steven Baert | Novartis AG ADR | 45 | |
| Bertrand Bodson | Novartis AG ADR | 44 | |
| Victoria Whyte | GlaxoSmithKline PLC ADR | N/A | |
| John Tsai | Novartis AG ADR | 54 | |
| Pierre Chancel | Sanofi ADR | 67 | |
| Deborah JD | Gilead Sciences | 59 | |
Management Performance
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0576 |
Bayer AG PK Leadership Team
Elected by the shareholders, the Bayer AG's board of directors comprises two types of representatives: Bayer AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bayer. The board's role is to monitor Bayer AG's management team and ensure that shareholders' interests are well served. Bayer AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bayer AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sarena Lin, Labor Officer | ||
| Oliver Maier, Head Relations | ||
| Gabriel Harnier, Patents Law | ||
| Heiko Schipper, Member of the Management Board, Head of the Consumer Health Division | ||
| Rodrigo Santos, Member Division | ||
| Michael Preuss, Gov Communications | ||
| Stefan Oelrich, Member of the Management Board, Head of the Pharmaceuticals Division | ||
| Wolfgang Nickl, CFO, Member of the Management Board | ||
| BerndPeter Bier, Head Taxes | ||
| Werner Baumann, Chief Strategy and Portfolio Officer and Member of Management Board |
Bayer Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Bayer AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0576 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.23 % | ||||
| Current Valuation | 87.41 B | ||||
| Shares Outstanding | 3.93 B | ||||
| Shares Owned By Institutions | 0.10 % | ||||
| Price To Earning | 12.46 X | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 1.02 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Bayer Pink Sheet
If you are still planning to invest in Bayer AG PK check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bayer AG's history and understand the potential risks before investing.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |